

1 **Review Article**

2  
3 **Inhibition of *Clostridium botulinum* and its Toxins by Probiotics and Their**  
4 **Nisin: An Update Review**

5  
6 **Adel Mirza Alizadeh<sup>1</sup>, Fataneh Hashempour-Baltork<sup>1</sup>, Mahmood Alizadeh-Sani<sup>2</sup>,**  
7 **Mohammad Maleki<sup>3</sup>, Maryam Azizi-Lalabadi<sup>4</sup>, Kianoush Khosravi-Darani<sup>5\*</sup>**

8  
9 <sup>1</sup> Student Research Committee, Department of Food Science and Technology, National Nutrition  
10 and Food Technology Research Institute, Faculty of Nutrition Science and Food Technology,  
11 Shahid Beheshti University of Medical Sciences, Tehran

12 <sup>2</sup> Student Scientific Research Center, Food Safety and Hygiene Division, Environmental Health  
13 Department, Tehran University of Medical Sciences, Tehran, Iran

14 <sup>3</sup> Department of Food Hygiene and Aquaculture, Ferdowsi University of Mashhad, Mashhad, Iran.

15 <sup>4</sup> Department of Food Science and Technology, School of Nutrition Sciences and Food  
16 Technology, Research Center for Environmental Determinants of Health, Kermanshah  
17 University of Medical Sciences, Kermanshah, Iran.

18 <sup>5</sup> Department of Food Science and Technology, National Nutrition and Food Technology Research  
19 Institute, Faculty of Nutrition Science and Food Technology, Shahid Beheshti University of  
20 Medical Sciences, Tehran, Iran

21  
22 **Running title:** bioremoval of *C. botulinum* toxins by probiotics

23  
24 **Correspondence**

25 Prof. Kianoush Khosravi-Darani, [k.khosravi@sbmu.ac.ir](mailto:k.khosravi@sbmu.ac.ir), [kiankh@yahoo.com](mailto:kiankh@yahoo.com),

26 Fax: 98-21-22376473

27 Tel: 98-21-22086348

28 **Abstract**

29 *Clostridium (C.) botulinum* is the causative agent of foodborne poisoning as botulism, which has  
30 a high mortality rate in animals and humans, when grows and produces toxins in food. Probiotic  
31 bacteria play a critical and functional role in food matrices, agricultural, clinical and nutritional  
32 applications. In this review, the ability of various probiotic bacteria and their metabolites to inhibit  
33 of *C. botulinum* toxicity was reviewed. For this purpose, an introduction about *C. botulinum* and  
34 its mechanism of action for pathogenicity is mentioned. After a short glance to probiotic bacteria  
35 and their beneficial health effects on human, the mechanism of their action are reviewed. Then the  
36 subject is directed to bacteriocins production by probiotic bacteria. After description of *C.*  
37 *botulinum* and its neurotoxins, the effects of probiotic bacteria on *C. botulinum* are reviewed with  
38 a special focus on impact of their bacteriocins on this pathogen. This study confirmed that probiotic  
39 bacteria and their bacteriocins (especially nisin) can be effective on the growth, toxin formation  
40 and toxicities of *C. botulinum* and its toxins. It could be recommended that probiotics consumption,  
41 perhaps from birth to all stages of life, would be effective in preventing or treating the toxicity of  
42 *C. botulinum*.

43  
44 **Keywords:** *Clostridium Botulinum*, Probiotic bacteria, Bacteriocin, Nisin, Decontamination,  
45 Safety

46

47

## 48 1. Introduction

49 The digestive system has a significant role in the digestion and absorption of food and energy. The  
50 gastrointestinal mucosa, which covers a lot of surface, is exposed to pathogens and non-pathogens  
51 environmental agents [1]. The microorganisms present in the gastrointestinal tract especially the  
52 *Lactobacillus* Sp. and *Bifidobacterium* Sp. play an important role in health [2]. These  
53 microorganisms have the greatest impact on immune system function and lead to the development  
54 of a strong and balanced immune system [3,2,4]. Since the largest and most complex part of the  
55 human immune system is located in the tissues of the gastrointestinal tract, therefore, revival  
56 immunity system plays a serious role in protecting human against various pathogens. If individual's  
57 gut microbiota- the microorganisms that usually colonize the body - balance changes due to the  
58 use of various drugs, including antibiotics, it can increase the risk of various infectious diseases  
59 by opportunistic pathogens such as clostridium [5,6].

60 *Clostridium* bacteria are a group of Gram-positive bacteria, obligate anaerobes, rod-shaped and  
61 producer endospores. These bacteria are known as foodborne pathogenic and spoilage bacteria and  
62 hazardous human pathogens [7]. The most important bacteria these group are *C. botulinum* (the  
63 causative agent of botulism), *C. difficile* (causing diarrhea during antibiotic therapy), *C.*  
64 *perfringens* (food poisoning to cellulitis and gas gangrene) and etc. [8]. *C. botulinum* is one of the  
65 most well-known members of this group, which leads to botulinum toxin production. Botulism  
66 disease affects different individuals, especially infants (transmitted through honey), and causes  
67 many complications, including paralysis, nausea, vomiting and abdominal cramps, difficulty  
68 swallowing or speaking, weak cry, irritability, drooping eyelids, tiredness, difficulty sucking or  
69 feeding [9]. On the other hand, *C. botulinum* produces various neurotoxins, which have different  
70 effects depending on the host's final, named type A-H. Therefore, controlling these pathogens by

biological, chemical and physical agents can have an effective role in providing the public health [10].

Today, the use of biologic agents in disease control has been considered by researchers due to the adverse effects of drug use on health. Among these biologic agents, can be mentioned to probiotics (health promoting) of the bacteria and their metabolites [11]. As defined, probiotics bacteria are considered as living microorganisms that, if consumed in sufficient amounts, have health effects on the host and lead to improving or restoring the gut microbiota. These microorganisms are mainly bacteria of the *Lactobacillus sp.* and *Bifidobacterium sp.* [12]. Recently, these microorganisms and their metabolite (for example bacteriocins) have been widely used in the food industries, pharmaceutical and medical due to safety (non-pathogenicity and antibiotic resistance) properties, technological and functional (survive and viability during storage, persistence in the gut-tract, anti-inflammatory, anti-mutagenic and immunomodulation) characteristics [12-14]. In addition, these microorganisms can be used to detoxify various compounds (mycotoxins, heavy metals and bacterial toxins) [15-17]. Therefore, the purpose of this review study is to investigate inhibition of *C. botulinum* bacteria by probiotics of bacteria and their metabolites.

## 2. Probiotic Bacteria

The term probiotic, which means 'for life' comes from the Greek 'pro bios'. The history of probiotics began with the history of man; So that it was well known by the Greeks and Romans with cheese and fermented dairy products. They recommended consumption these substances, especially for children, seniors and convalescents for their health effects [3]. Moreover, prebiotics usually known as non-digestible food compounds (Fibers, Oligosaccharides, Chicory root, Garlic, Leek, Onion, Banana and etc.) that are selectively used by gut microbiota for fermentation. These

94 compounds stimulate the growth or activity of beneficial microorganisms. Furthermore, these  
95 bacteria are related with lucrative health aftereffects can be specifically targeted. Considering the  
96 available evidence that prebiotics can alter the gastrointestinal microbiota. But it's not yet clear  
97 quietly how changes in the microbiota composition and performance by prebiotics, how stable  
98 these alters and how the effects of these changes on human health. Therefore, these characteristics  
99 will need to be investigated further [5]

100 Probiotics can be found in dairy and non-dairy products [3]. Currently, preparation of probiotics  
101 is chiefly based on acid-lactic bacteria (*Lactobacilli*, *Streptococci*, and *Bifidobacteria*). These  
102 bacterial genera are usually harmless to health and have proven to be important components of the  
103 gut-tract microbiota [18]. Lactic acid bacteria (LAB) are Gram-positive bacteria, non-sporulating,  
104 anaerobic or facultative aerobic cocci or rods, which, by fermentation and metabolism of  
105 carbohydrates, produce lactic acid as one of the main metabolite [19]. Acceptable level of bacteria  
106 in probiotic food products at the end of their shelf life is to have up to  $10^7$  CFU/g [20]; but, since  
107 the probiotics must withstand some conditions and stresses in the target location to elicit their  
108 effect. Therefore, the human gut tract must be contains up to  $10^{13}$  -  $10^{14}$  cells to ensure they reach  
109 the sufficient numbers [21].

110 The term probiotic is mostly related to lactic acid bacteria (*Lactobacillus* and *Bifidobacterium* Sp.),  
111 but, it can also be applied to other microorganisms. For example, some *Bacillus* (*B.*) species  
112 including *B. subtilis*, *B. clausii*, *B. cereus*, *B. coagulans* and *B. licheniformis* have been used as  
113 probiotics for at least 50 years in an Italian product commercialized as Enterogermina ( $2 \cdot 10^9$   
114 spores) [22].

115 The main sections of the human digestive tract (the stomach, the small intestine, and the large  
116 intestine) have their own distinct microbiota [21,23-25]. The aerobic Gram-positive bacteria are

117 mostly inhabited in the stomach ( $<10^3$  CFU/g). The genera *Lactobacillus* spp., *Bifidobacterium*  
118 spp., *Bacteroides* spp., and *Streptococcus* spp. are inhabited in the small intestine ( $10^3 - 10^4$   
119 CFU/g), and the genera *Bacteroides* spp., *Fusobacterium* spp., *Lactobacillus* spp., *Bifidobacterium*  
120 spp., and *Eubacterium* spp. are inhabited in the large intestine in large numbers ( $10^{11} - 10^{12}$  CFU/g).  
121 There are many studies of the probiotics effects of LAB [26]. The most popular probiotic  
122 microorganisms with claimed health benefits for humans and animals are represented in Figure 1  
123 [27,3,28-30]. They have been isolated from various sources like dairy products, plants, fermented  
124 meat products, pickled fruits and vegetables, beverages, soy sauce, marinated fish products and  
125 fermented cereal products.

126

127

### Figure 1

128 **Fig. 1** Probiotic microorganisms with claimed health benefits for humans and animals

129

### 130 **2.1 Mechanisms action of probiotic bacteria**

131 Probiotics may be applied their beneficial health effects in the three modes [11]: a) Adjusting the  
132 host defense system including the inherent and acquired immune systems; b) Direct or indirect  
133 effects on other microorganisms, pathogens, and commensal.; c) Effect on the metabolites of  
134 microorganisms like toxins and host products, e.g. bile salts and food ingredients. Deactivating  
135 toxins and detoxifying host and other food compounds in the digestive tract may be done by  
136 various activities. For this purpose, probiotics may use a dual effect, prevent or reduce the  
137 colonization of pathogen microorganisms in the intestines [31], or interacting with the gut-  
138 associated lymphoid tissue (GALT) to prevent inflammatory responses and reinforce their own  
139 tolerance and possibly to food [32]. The useful effects of probiotics are usually varied and specific  
140 [33]. Some species participate in the treatment of acute diarrhea associated with rotavirus [34],

141 ulcerative colitis [35,36], *Clostridium difficile*-associated diarrhea [37], and *Helicobacter pylori*  
142 infection [38,39].

143

## 144 **2.2 Bacteriocins produced by probiotic bacteria**

145 Bacteriocins, defined as probiotics metabolites, are classified into four groups on the basis of to  
146 their molecular mass, thermo-stability, enzymatic sensitivity, presence of modified amino acids,  
147 and mechanism of action [40]. Class I: are small peptide inhibitors and include nisin and other  
148 lantibiotics; Class II: This group comprises heat-stable peptides with molecular weight smaller  
149 than 10 kDa and with no modified amino acid; Class III: This group consists of peptidic antibiotics  
150 that are heat-labile proteins with a molecular weight larger than 30 kDa; Class IV: This group  
151 contain either glycoproteins or lipoproteins that require non-protein moieties for their activity [41].  
152 As presented in Table 1, there are several of bacteriocins which can be produced by types of  
153 probiotic bacteria. Nisin, one of the most important bacteriocin, is the prototype lantibiotic  
154 (amphipathic antibiotic peptide) from *Lactococcus lactis* and *Streptococcus lactis* which is active  
155 against certain Gram-positive and Gram-negative bacteria at the nanomolar range. The  
156 biosynthesis of nisin involves synthesis of ribosomal peptide, dehydration of serine and threonine  
157 amino acids residues, cyclization through sulfhydryl increment of cysteine to a dehydrated residue,  
158 transmission of the precursor peptide and proteolytic activation (Figure 2a). The Hinge region of  
159 nisin, formed of 3 amino acids (residues NMK), is implicated to play an important task during  
160 insertion of nisin's C-terminus into the cell membrane [42]. As shown in figure 2b, there are two  
161 inhibition or killing mechanisms of nisin in a bacterial cell. It can be bind to lipid II (is located in  
162 the cell membrane and plays a fundamental role in wall synthesis) and causes pore formation. The  
163 second mechanism is interfering and prevention of cell wall biosynthesis [43-45].

164 **Figure 2**  
165 **Fig. 2 a)** Structure of nisin A. Dhb, dehydrobutyrine; Dha, dehydroalanine; Abu-S-Ala,  $\beta$ -  
166 methylanthionine; Ala-S-Ala, lanthionine; Hinge region (Asn-Met-Lys) [43]. **b)** Mechanism of  
167 action of Nisin in the cell of bacteria [46].  
168  
169  
170

171 **Table 1 near here**  
172  
173

### 174 **3. *C. botulinum* and its Neurotoxins**

175 Clostridium bacteria, an anaerobic spore former, are widely found in nature, environment and the  
176 intestines of humans and animals and foodstuffs, especially fresh meat, drinks, milk and canned  
177 food [9]. These bacteria produce spores and are very resistant to heat. Among the various species,  
178 *C. botulinum*, causes serious food poisoning associated with meats, fish, and vegetables [50]. *C.*  
179 *botulinum* strains are categorized into four biotype groups based on their toxin type and proteolytic  
180 capabilities (Table 2). Group I consists of all type A and some (proteolytic) type B strains, and is  
181 characterized as highly proteolytic, group II strains are only weakly or non-proteolytic and consists  
182 of non-proteolytic type B and all type E strains. Strains of both groups differ in their relative  
183 heat resistance, maximum and minimum growth temperatures, and tolerance to acid and salt.  
184 Strains in groups III and IV are not commonly considered with foodborne human botulism  
185 [51,10,52]. Optimum and minimum temperature of growth for proteolytic strains are 37°C and  
186 10°C, respectively. Non proteolytic strains grow and produce toxins at temperatures as low as 3.3  
187 to 4.0°C [10]. Therefore, preserve of minimally processed refrigerated foods at temperatures  
188 higher than 10°C will result in botulism hazard if spores survived the pasteurization process [53].  
189 The sodium chloride and nitrite, at refrigeration temperatures, have synergistic impact on *C.*  
190 *botulinum* spores, especially in cured meats [53]. The role of nitrite in nitrosamine formation in  
191 cured meats caused to the search for an anti-botulinum agent [54]. ]. Botulinum neurotoxins are a



192 metalloprotease (150-kDa) and including a heavy chain (100-kDa) and a light chain (50-kDa) that  
193 linked by a disulfide bond [10,51]. The neurotoxin blocks releasing acetylcholine from the motor  
194 nerve-endings and leading to paralysis in human and animal [55]. *C. Botulinum* causes three major  
195 diseases in humans including foodborne botulism, infant botulism and wound botulism. The toxin  
196 usually is destroyed by heating (80°C/20 min or 85°C/5 min). Since the neurotoxin is completely  
197 tasteless and odorless, so foods that contain neurotoxin may not show any warning signs to the  
198 consumer [55,56].

199

200

**Table 2 near here**

201

#### 202 **4. The effects of probiotic bacteria on *C. botulinum***

203 Botulinum neurotoxins are generated by the gram-positive, anaerobic spore-forming Clostridium  
204 species and are the causative agent of botulism [58]. There are at least 7-8, different serotypes of  
205 Botulinum neurotoxins that four serotypes A, B, E, and F causes of botulism in humans [59].  
206 Botulinum neurotoxins are highly poisonous to humans with the have lethal and oral dosage of  
207 0.1–1 ng/kg and 1 µg/kg, respectively. Botulinum neurotoxins lead to a public health and safety  
208 threat in the form of foodborne, wound, and infant botulism. Because of its mortality and  
209 morbidity, there is a considerable economic burden associated with the long-term handling of  
210 intoxication [60,61]. The first function in botulinum neurotoxins defection and foodborne illnesses  
211 is, surviving in gastrointestinal tract, then should be bind and translocate through the intestinal  
212 epithelium to reach the bloodstream. Based on previous research a complex of botulinum toxin  
213 serotype A- which is combination of holotoxin with neurotoxin-associated proteins- binds and  
214 transits through the intestinal epithelia to disseminate in the blood faster than botulinum toxin

210 serotype A holotoxin alone [55,62]. Hence, perception the mechanism(s) in which botulinum  
211 neurotoxins bind to and breach this epithelial barrier is of excellent scientific benefit because of  
212 the potential expansion of novel therapeutics to prevent this required first step of oral intoxication  
213 [62].

214 Nowadays; researcher have provided incentive document that probiotic microorganisms are  
215 precious in the prohibition and treatment a number of diseases and disorder. Today, the use of  
216 probiotics has increased dramatically due to our growing awareness of the beneficial effects of  
217 these microorganisms and how each of the strains acts in specific conditions [63]. It should be  
218 noted that these definitions are consistent with the definitions provided by WHO organization  
219 [63,64]. Recent study about probiotic such as lactobacillus, concentrate on the interaction of them  
220 with immune system [65], and their effect as an anticancer and bio-therapeutic agent. Probiotics  
221 microorganism have a great potential in treatment some diseases such as *Helicobacter pylori*  
222 infection, irritable bowel syndrome, and inflammatory bowel disease as well as boosting the  
223 immune system of healthy individuals [66-68]. The most commonly probiotic strains used are  
224 *Lactobacillus spp.*, *Bifidobacteria spp.*, and the yeast strain *Saccharomyces cerevisiae* var.  
225 *boulardii*. Lactic acid bacteria and Bifidobacteria have good ability in removing heavy metals [69]  
226 cyanotoxins [11], and mycotoxin from in vitro aqueous solutions[70]. The probiotic impacts seen  
227 are both strain and species dependent showing that combinations of vary strains and species may  
228 require to be suitable to the special subject at hand rather than having one “universal” probiotic  
229 therapy. Although many advantage characteristics of probiotics have been displayed in both in  
230 vivo and in vitro research, the accurate mechanism(s) that is responsible for these beneficial effects  
231 remains to be fully elucidated. These mechanisms which have related to probiotics are: (a)  
232 conservation of the gut epithelial barrier, (b) competitive elimination of pathogenic

microorganisms, (c) secretion of antimicrobial products, and (d) regulation of the mucosal immune system in favor of the hosts [11,71].

240.

## 241 **5. The effects of bacteriocins on *C. botulinum***

242 Bacteriocins are proteinaceous or peptidic toxins produced by bacteria to inhibit the growth of  
243 similar or closely related bacterial strain(s). They are various structurally, functionally, and  
244 ecologically. Applications of bacteriocins are being tested to assess their application as narrow-  
245 spectrum antibiotics. Activity of bacteriocin is depended to the properties of the given food system  
246 [72]. Generally, nisin is most effective at a pH of <6.0 in low-fat and -protein foods [73]. The use  
247 of bacteriocins to prevent pathogens is particularly attractive in some components such as  
248 minimally processed refrigerated meats. *Listeria (L.) monocytogenes* and *C. botulinum* are of  
249 particular concern in minimally processed refrigerated meats because of their susceptibility and  
250 heat resistant spores of these product which caused to grow and produce toxin in temperature-  
251 abused food [74,75]. Many lactic acid bacteria have excellent ability in producing bacteriocins to  
252 inhibit of *L. monocytogenes*, *C. botulinum* and a broad range of Gram-positive and Gram-negative  
253 foodborne pathogens [76,77]. *C. botulinum* is one of the more nisin-resistant clostridial species  
254 [78]. Twenty-three strains of Lactic acid bacteria were assessing for bacteriocins-like activity  
255 against types A and B spores from proteolytic and non-proteolytic *C. botulinum* strains [79].  
256 *Pediococcus pentosaceus* ATCC 43200, *Pediococcus pentosaceus* ATCC 43201, *Lactococcus*  
257 *lactic subsp. lactic* ATCC 11454, *Lactobacillus acidophilus* N2, *Lactobacillus plantarum* Lb75,  
258 *Lactobacillus plantarum* Lb592, and *Lactobacillus plantarum* BN demonstrated bacteriocins-like  
259 inhibition of all *C. botulinum* strains tested. Based on the minimum inhibitory concentrations,  
260 *Pediococcus pentosaceus* 43200 was most inhibitory to *C. botulinum* [80].

261 Nisin is one of common bacteriocin produced by *Lactococcus lactis* and show wide activity against  
262 Gram-positive bacteria including *Listeria*, *Bacillus*, *Clostridium*, *Staphylococcus*, *Streptococcus*,  
263 *Lactobacillus*, and *Micrococcus* [81-83]. In the United States, nisin has a generally-recognized-as-  
264 safe (GRAS) application to inhibit *C. botulinum* spore. Application of nisin was approved in the  
265 United States in April 1988, although its function is limited to certain pasteurized process cheese  
266 [84]. As regards *C. botulinum* can grow in minimally processed refrigerated foods [85] which  
267 might be destroyed by usage of nisin [86-88]. The synergistic impacts of nisin and heat treatment  
268 on *C. botulinum* have been study by Scott and Taylor [89]. Some study investigated the sensitivity  
269 of six *C. botulinum* strains to nisin and exhibit that type A are more resistance followed by B and  
270 E. While this study evaluated that proteolytic strains are more resistant to nisin than saccharolytic  
271 strains [89], but Rayman et al. have found proteolytic and non-proteolytic type B spores were  
272 equally resistant to nisin [90]. Growth conditions and food components also affect nisin's  
273 effectiveness. Factors decreasing nisin's ability to inhibit *C. botulinum* growth include low acid  
274 environment, short heat-shocking periods, high spore load, high protein and phospholipid  
275 concentrations, and increased incubation temperature [91,89].

276

## 277 **6. Conclusion**

278 Considering the importance of pathogenicity and the mortality rate of by *C. botulinum*, and its  
279 role in food poisoning, Therefore, control of this pathogen and neurotoxins produced by it, is  
280 required by various factors. Probiotics and their metabolites (bacteriocins) as biological control  
281 agents play an important role in detoxification and reduce the risk by these pathogens. On the  
282 other hand, the relation of antagonism between *C. botulinum* and bacterial members of the  
283 ecosystem are well known. Accordingly, researchers concluded that the use of probiotics and

۲۸۴ metabolites could help in the prevention of *C. botulinum* colonization and reduce botulinum  
 ۲۸۵ neurotoxin production.

۲۸۶

### ۲۸۷ **Acknowledgments**

۲۸۸ This study is related to the project NO. 1397/68940 from Student Research Committee, Shahid  
 ۲۸۹ Beheshti University of Medical Sciences, Tehran, Iran. We also appreciate the “Student Research  
 ۲۹۰ Committee” and “Research & Technology Chancellor” in Shahid Beheshti University of Medical  
 ۲۹۱ Sciences for their financial support of this study.

۲۹۲ **Funding** The work was supported by the financial support of Student Research Committee, Shahid  
 ۲۹۳ Beheshti University of Medical Sciences, Tehran, Iran, project NO. 1397/68940.

### ۲۹۴ **Compliance with Ethical Standards**

۲۹۵ **Conflict of Interest** No potential conflict of interest was reported by the authors.

۲۹۶ **Ethical Approval** We state that this article does not contain any studies with human participants  
 ۲۹۷ or animals performed by any of the authors.

۲۹۸ **Informed Consent** For this type of study, formal consent is not required.

۲۹۹

### ۳۰۰ **References**

- ۳۰۱ 1. Donaldson GP, Lee SM, Mazmanian SK (2016) Gut biogeography of the bacterial microbiota.  
 ۳۰۲ Nat Rev Microbiol 14 (1):20
- ۳۰۳ 2. Butel M-J (2014) Probiotics, gut microbiota and health. Méd Mal Infect 44 (1):1-8
- ۳۰۴ 3. Socol CR, de Souza Vandenberghe LP, Spier MR, Medeiros AP, Yamaguishi CT, De Dea  
 ۳۰۵ Lindner J, Pandey A, Thomaz-Socol V (2010) The potential of probiotics: a review. Food  
 ۳۰۶ Technol Biotech 48 (4):413-434
- ۳۰۷ 4. Hashempour-Baltork F, Hosseini H, Shojae-Aliabadi S, Torbati M, Alizadeh AM, Alizadeh  
 ۳۰۸ M (2019) Drug Resistance and the Prevention Strategies in Food Borne Bacteria: An Update  
 ۳۰۹ Review. APB 9 (3):335
- ۳۱۰ 5. Bäckhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, Versalovic J, Young  
 ۳۱۱ V, Finlay BB (2012) Defining a healthy human gut microbiome: current concepts, future  
 ۳۱۲ directions, and clinical applications. Cell host microbe 12 (5):611-622

- 313 6. Sánchez B, Delgado S, Blanco-Míguez A, Lourenço A, Gueimonde M, Margolles A (2017)  
314 Probiotics, gut microbiota, and their influence on host health and disease. *Mol Nutr Food*  
315 *Res* 61 (1):1600240
- 316 7. Lund BM (1990) Foodborne disease due to *Bacillus* and *Clostridium* species. *Lancet* 336 (Oct.  
317 20):982-986
- 318 8. Hatheway CL (1990) Toxigenic clostridia. *Clin Microbiol Rev* 3 (1):66-98
- 319 9. Fooda (2018) Food poisoning with *Clostridium botulinum*. <http://fooda.ir>. Accessed  
320 30/11/2018
- 321 10. Sugiyama H (1980) *Clostridium botulinum* neurotoxin. *Microbiol Rev* 44 (3):419
- 322 11. Oelschlaeger TA (2010) Mechanisms of probiotic actions—a review. *Int J Med Microbiol* 300  
323 (1):57-62
- 324 12. Verschuere L, Rombaut G, Sorgeloos P, Verstraete W (2000) Probiotic bacteria as biological  
325 control agents in aquaculture. *Microbiol Mol Biol R* 64 (4):655-671
- 326 13. Saarela M, Mogensen G, Fonden R, Mättö J, Mattila-Sandholm T (2000) Probiotic bacteria:  
327 safety, functional and technological properties. *J Biotechnol* 84 (3):197-215
- 328 14. Shah N (2000) Probiotic bacteria: selective enumeration and survival in dairy foods. *J Dairy*  
329 *Sci* 83 (4):894-907
- 330 15. Lam TI, Tam CC, Stanker LH, Cheng LW (2016) Probiotic microorganisms inhibit epithelial  
331 cell internalization of botulinum neurotoxin serotype A. *Toxins* 8 (12):377
- 332 16. Shetty PH, Jespersen L (2006) *Saccharomyces cerevisiae* and lactic acid bacteria as potential  
333 mycotoxin decontaminating agents. *Trends Food Sci Technol* 17 (2):48-55
- 334 17. Zoghi A, Khosravi-Darani K, Sohrabvandi S (2014) Surface binding of toxins and heavy  
335 metals by probiotics. *Mini Rev Med Chem* 14 (1):84-98
- 336 18. Fuller R (1991) Probiotics in human medicine. *Gut* 32 (4):439
- 337 19. Hayek SA, Ibrahim SA (2013) Current limitations and challenges with lactic acid bacteria: a  
338 review. *Food Nutr Sci* 4 (11):73
- 339 20. Corcoran B, Ross R, Fitzgerald G, Dockery P, Stanton C (2006) Enhanced survival of  
340 GroESL-overproducing *Lactobacillus paracasei* NFBC 338 under stressful conditions  
341 induced by drying. *Appl environ* 72 (7):5104-5107
- 342 21. Savage DC (1977) Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol* 31  
343 (1):107-133
- 344 22. Cutting SM (2011) *Bacillus* probiotics. *Food Microbiol* 28 (2):214-220.  
345 doi:<https://doi.org/10.1016/j.fm.2010.03.007>
- 346 23. Simon GL, Gorbach SL (1984) Intestinal flora in health and disease. *Gastroenterology* 86  
347 (1):174-193
- 348 24. Mills S, Stanton C, Fitzgerald GF, Ross R Enhancing the stress responses of probiotics for a  
349 lifestyle from gut to product and back again. In: *Microbial cell factories*, 2011. vol 1.  
350 BioMed Central, p S19
- 351 25. Dethlefsen L, Eckburg PB, Bik EM, Relman DA (2006) Assembly of the human intestinal  
352 microbiota. *Trends ecol evol* 21 (9):517-523
- 353 26. Montville TJ, Matthews KR (2007) *Food microbiology: an introduction*. vol Ed. 2. ASM  
354 Press, Washington DC
- 355 27. Fijan S (2014) Microorganisms with claimed probiotic properties: an overview of recent  
356 literature. *Int J Environ Res Public Health* 11 (5):4745-4767
- 357 28. Stiles ME (1996) Biopreservation by lactic acid bacteria. *Antonie van leeuwenhoek* 70 (2-  
358 4):331-345

29. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, Fakiri EM (2013) Health benefits of probiotics: a review. *ISRN Nutr* 2013:481651. doi: 10.5402/2013/481651.
30. Bintsis T (2018) Lactic acid bacteria: their applications in foods. *J Bacteriol Mycol* 6 (2):89-94
31. Arvola T, Laiho K, Torkkeli S, Mykkänen H, Salminen S, Maunula L, Isolauri E (1999) Prophylactic *Lactobacillus GG* Reduces Antibiotic-Associated Diarrhea in Children With Respiratory Infections: A Randomized Study. *Pediatrics* 104 (5):e64-e64
32. Turcanu V, Lack G (2006) Molecular and Immunological Responses to Food. In: *Food Allergy*. American Society of Microbiology, Washington DC,, pp 83-121
33. Ebel B, Lemetais G, Beney L, Cachon R, Sokol H, Langella P, Gervais P (2014) Impact of probiotics on risk factors for cardiovascular diseases. A review. *Crit Rev Food Sci Nutr* 54 (2):175-189
34. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T (1995) Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by *Lactobacillus casei GG*. *Vaccine* 13 (3):310-312
35. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T (2003) Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. *J Am Coll Nutr* 22 (1):56-63
36. Kruis W, Frič P, Pokrotnieks J, Lukáš M, Fixa B, Kaščák M, Kamm M, Weismueller J, Beglinger C, Stolte M (2004) Maintaining remission of ulcerative colitis with the probiotic *Escherichia coli* Nissle 1917 is as effective as with standard mesalazine. *Gut* 53 (11):1617-1623
37. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z (1994) A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *Jama* 271 (24):1913-1918
38. Nista EC, Candelli M, Cremonini F, Cazzato IA, Zocco MA, Franceschi F, Cammarota G, Gasbarrini G, Gasbarrini A (2004) *Bacillus clausii* therapy to reduce side-effects of anti-*Helicobacter pylori* treatment: randomized, double-blind, placebo controlled trial. *Aliment pharm ther* 20 (10):1181-1188
39. Wang Y, Jones PJ (2004) Conjugated linoleic acid and obesity control: efficacy and mechanisms. *Int J Obes* 28 (8):941
40. Klaenhammer TR (1993) Genetics of bacteriocins produced by lactic acid bacteria. *FEMS microbiol Rev* 12 (1-3):39-85
41. Nishant T, Sathish K, Arun K, Hima B, Raviteja Y (2011) Bacteriocin producing probiotic lactic acid bacteria. *J Microbial Biochem Technol* 3:5
42. Hasper HE, de Kruijff B, Breukink E (2004) Assembly and stability of nisin– lipid II pores. *Biochemistry* 43 (36):11567-11575
43. Zhou L, van Heel AJ, Kuipers OP (2015) The length of a lantibiotic hinge region has profound influence on antimicrobial activity and host specificity. *Front microbiol* 6:11
44. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl H-G (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. *J Biol Chem* 276 (3):1772-1779



45. Breukink E, de Kruijff B (2006) Lipid II as a target for antibiotics. *Nat Rev Drug Discov* 5 (4):321
46. Raybaudi-Massilia RM, Mosqueda-Melgar J, Soliva-Fortuny R, Martín-Belloso O (2009) Control of pathogenic and spoilage microorganisms in fresh-cut fruits and fruit juices by traditional and alternative natural antimicrobials. *Compr Rev Food Sci* 8 (3):157-180
47. Ghalfi H, Benkerroum N, Ongena M, Bensaid M, Thonart P (2010) Production of three anti-listerial peptides by *Lactobacillus curvatus* in MRS broth. *Food Res Int* 43 (1):33-39. doi:<https://doi.org/10.1016/j.foodres.2009.08.009>
48. Hammami R, Zouhir A, Le Lay C, Hamida JB, Fliss I (2010) BACTIBASE second release: a database and tool platform for bacteriocin characterization. *Bmc Microbiol* 10 (1):22
49. Gillor O, Etzion A, Riley M (2008) The dual role of bacteriocins as anti-and probiotics. *Appl Microbiol Biotechnol* 81 (4):591-606
50. Dodds KL (1993) *Clostridium botulinum* in foods. *Clostridium botulinum: ecology and control in foods*:53-68
51. Nadjafi M, Hamzeh PS (2017) Botulinum Neurotoxins, a Real Bioterrorism Threat: A Classic Review. *Nurse and Physician Within War* 13
52. Turton K, Chaddock JA, Acharya KR (2002) Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. *Trends Bioch Sci* 27 (11):552-558
53. Alahakoon AU, Jayasena DD, Ramachandra S, Jo C (2015) Alternatives to nitrite in processed meat: Up to date. *Trends Food Sci Technol* 45 (1):37-49
54. Cui H, Gabriel AA, Nakano H (2010) Antimicrobial efficacies of plant extracts and sodium nitrite against *Clostridium botulinum*. *Food Control* 21 (7):1030-1036
55. Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. *Nat Rev Microbiol* 12 (8):535
56. Nigam P, Nigam A (2010) Botulinum toxin. *Indian J Dermatol* 55 (1):8
57. Jay JM, Loessner MJ, Golden DA (2005) *Modern food microbiology*. 7 edn. Springer US, New York
58. Eubanks LM, Šilhár P, Salzameda NT, Zakhari JS, Xiaochuan F, Barbieri JT, Shoemaker CB, Hixon MS, Janda KD (2010) Identification of a natural product antagonist against the botulinum neurotoxin light chain protease. *ACS Med Chem Lett* 1 (6):268-272
59. Gonzalez-Escalona N, Thirunavukkarasu N, Singh A, Toro M, Brown EW, Zink D, Rummel A, Sharma SK (2014) Draft genome sequence of bivalent *Clostridium botulinum* strain IBCA10-7060, encoding botulinum neurotoxin B and a new FA mosaic type. *Genome announce* 2 (6):e01275-01214
60. Tighe AP, Schiavo G (2013) Botulinum neurotoxins: mechanism of action. *Toxicon* 67:87-93
61. Rummel A (2015) The long journey of botulinum neurotoxins into the synapse. *Toxicon* 107:9-24
62. Lam TI, Stanker LH, Lee K, Jin R, Cheng LW (2015) Translocation of botulinum neurotoxin serotype A and associated proteins across the intestinal epithelia. *Cell Microbiol* 17 (8):1133-1143
63. Gioacchini G, Lombardo F, Merrifield D, Silvi S, Cresci A, Avella M, Carnevali O (2011) Effects of probiotics on Zebrafish reproduction. *J Aquac Res Dev S* 1
64. Postollec F, Falentin H, Pavan S, Combrisson J, Sohier D (2011) Recent advances in quantitative PCR (qPCR) applications in food microbiology. *Food microbiol* 28 (5):848-861



- 449 65. Durlu-Özkaya F, Özkaya MT (2011) Oleuropein using as an additive for feed and products  
 450 used for humans. *Journal of Food Processing and Technology* 2 (3)  
 451 66. Dang Y, Reinhardt JD, Zhou X, Zhang G (2014) The effect of probiotics supplementation on  
 452 *Helicobacter pylori* eradication rates and side effects during eradication therapy: a meta-  
 453 analysis. *PloS one* 9 (11):e111030  
 454 67. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM  
 455 (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic  
 456 review. *Gut* 59 (3):325-332  
 457 68. Chapman C, Gibson GR, Rowland I (2011) Health benefits of probiotics: are mixtures more  
 458 effective than single strains? *Eur J Nutr* 50 (1):1-17  
 459 69. Bhakta J, Ohnishi K, Munekage Y, Iwasaki K, Wei M (2012) Characterization of lactic acid  
 460 bacteria-based probiotics as potential heavy metal sorbents. *J Appl Microbiol* 112 (6):1193-  
 461 1206  
 462 70. Dalié D, Deschamps A, Richard-Forget F (2010) Lactic acid bacteria—Potential for control of  
 463 mould growth and mycotoxins: A review. *Food control* 21 (4):370-380  
 464 71. Salminen S, Nybom S, Meriluoto J, Collado MC, Vesterlund S, El-Nezami H (2010)  
 465 Interaction of probiotics and pathogens—benefits to human health? *Curr Opin Biotech* 21  
 466 (2):157-167  
 467 72. Noordiana N, Fatimah A, Mun A (2013) Antibacterial agents produced by lactic acid bacteria  
 468 isolated from Threadfin Salmon and Grass Shrimp. *Int Food Res J* 20 (1)  
 469 73. Chikindas ML, Weeks R, Drider D, Chistyakov VA, Dicks LM (2018) Functions and  
 470 emerging applications of bacteriocins. *Curr Opin Biotech* 49:23-28  
 471 74. Bonsaglia E, Silva N, Júnior AF, Júnior JA, Tsunemi M, Rall V (2014) Production of biofilm  
 472 by *Listeria monocytogenes* in different materials and temperatures. *Food control* 35 (1):386-  
 473 391  
 474 75. Kasalica A, Vuković V, Vranješ A, Memiši N (2011) *Listeria monocytogenes* in milk and  
 475 dairy products. *Biotech Anim Husbandry* 27 (3):1067-1082  
 476 76. Reis J, Paula A, Casarotti S, Penna A (2012) Lactic acid bacteria antimicrobial compounds:  
 477 characteristics and applications. *Food Eng Rev* 4 (2):124-140  
 478 77. Gálvez A, Abriouel H, Benomar N, Lucas R (2010) Microbial antagonists to food-borne  
 479 pathogens and biocontrol. *Curr Opinion Biotech* 21 (2):142-148  
 480 78. Zhou H, Fang J, Tian Y, Lu XY (2014) Mechanisms of nisin resistance in Gram-positive  
 481 bacteria. *Ann Microbiol* 64 (2):413-420  
 482 79. Cizeikiene D, Juodeikiene G, Paskevicius A, Bartkiene E (2013) Antimicrobial activity of  
 483 lactic acid bacteria against pathogenic and spoilage microorganism isolated from food and  
 484 their control in wheat bread. *Food Control* 31 (2):539-545  
 485 80. Dobson A, Cotter PD, Ross RP, Hill C (2012) Bacteriocin production: a probiotic trait? *Appl*  
 486 *Environ Microbiol* 78 (1):1-6  
 487 81. Taylor LY, Cann DD, Welch BJ (1990) Antibotulinal properties of nisin in fresh fish  
 488 packaged in an atmosphere of carbon dioxide. *J Food Prot* 53 (11):953-957  
 489 82. Benkerroum N, Sandine WE (1988) Inhibitory action of nisin against *Listeria*  
 490 *monocytogenes*. *J Dairy Sci* 71 (12):3237-3245  
 491 83. Carminati D, Giraffa G, Bossi MG (1989) Bacteriocin-like inhibitors of *Streptococcus lactis*  
 492 against *Listeria monocytogenes*. *J Food Prot* 52 (9):614-617  
 493 84. Federal R (1988) Nisin preparation affirmation of GRAS status as a direct human ingredient.  
 494 *Food Registration* 54:11247-11251

- 490 85. Notermans S, Dufrenne J, Lund B (1990) Botulism risk of refrigerated, processed foods of  
496 extended durability. *J Food Prot* 53 (12):1020-1024
- 497 86. Chung K-T, Dickson JS, Crouse JD (1989) Effects of nisin on growth of bacteria attached to  
498 meat. *Appl Environ Microbiol* 55 (6):1329-1333
- 499 87. Denny CB, Sharpe LE, Bohrer CW (1961) Effects of tylosin and nisin on canned food  
500 spoilage bacteria. *J Appl Microbiol* 9 (2):108-110
- 501 88. Fowler GC (1981) Nisin: will it be used here? *J Food Eng* 53 (5):82-83
- 502 89. Scott VN, Taylor SL (1981) Temperature, pH, and spore load effects on the ability of nisin to  
503 prevent the outgrowth of *Clostridium botulinum* spores. *J Food Sci* 46 (1):121-126
- 504 90. Rayman M, Aris B, Hurst A (1981) Nisin: a possible alternative or adjunct to nitrite in the  
505 preservation of meats. *Appl Environ Microbiol* 41 (2):375-380
- 506 91. Rogers AM, Montville TJ (1994) Quantification of factors which influence nisin's inhibition  
507 of *Clostridium botulinum* 56A in a model food system. *J Food Sci* 59 (3):663-668
- 508
- 509